Bovilis BVD Suspension for injection for cattle 50ml (25 Dose)

Target species Cattle (cows and heifers). Indications for use For active immunisation of cows and heifers from eight months of age onwards to protect the foetus against transplacental infection with bovine viral diarrhoea virus. Contraindications None. Special warnings for each target species Vaccinate healthy animals only. Special precaution for use Not applicable. Operator warnings In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. Adverse reactions In very rare cases a slight swelling may be observed for 14 days at the site of injection. Also in very rare cases transient mild pyrexia may occur. In very rare cases, hypersensitivity reactions including anaphylactic shock may occur. In the event of anaphylactic type reactions, appropriate treatment such as with antihistamine, corticosteroid or adrenaline is recommended. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). Use during pregnancy or lactation Can be used during pregnancy. Interactions Safety and efficacy data are available which demonstrate that for re-vaccination -in cattle from 15 months of age onwards (i.e. those that have previously been vaccinated separately with Bovilis BVD and Bovilis IBR Marker Live) - this vaccine can be mixed and administered with Bovilis IBR Marker Live (in Member States where this veterinary medicinal product is authorised). The product literature of Bovilis IBR Marker Live should be consulted before administration of the mixed products. The adverse effects observed after administration of one dose or an overdose of the mixed vaccines are not different from those described for the vaccines administered separately. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.